GlassScriptPhysician profile
Brian Walter Temple
NPI 1689863649
$5,761.57
in general payments reported to CMS, 2019-2025
29 companies · $697 in 2025
The $697 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $508 · 2021: $1,241 · 2022: $1,049 · 2023: $784 · 2024: $960 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,441.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,531.77 | 2019-2024 | Jornay Pm |
| Corium, LLC | $693.63 | 2021-2025 | Azstarys |
| Neos Therapeutics, LP | $658.27 | 2019-2025 | Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $496.31 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $428.46 | 2019-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $240.95 | 2019-2024 | Doc Band |
| Collegium Pharmaceutical, INC. | $226.29 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $212.97 | 2019-2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $212.63 | 2020-2021 | |
| Adlon Therapeutics L.P. | $187.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $151.93 | 2020-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Noven Therapeutics, LLC | $111.74 | 2024-2025 | Xelstrym |
| Aytu Biopharma, INC. | $76.02 | 2020-2024 | Karbinal |
| Kaleo, INC. | $68.25 | 2019-2023 | Auvi-Q |
| Arbor Pharmaceuticals, INC. | $64.55 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.15 | 2019-2020 | |
| Phadia US INC. | $44.86 | 2022-2023 | Immunocap |
| Sanofi Pasteur INC. | $35.39 | 2019-2021 | |
| Glaxosmithkline, LLC. | $32.83 | 2022 | |
| Genentech USA, INC. | $31.29 | 2019-2021 | |
| Integra Lifesciences Corporation | $28.75 | 2024 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Alk-Abello, INC | $28.63 | 2025 | Neffy |
| Acclarent, INC | $25.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.00 | 2023 | Flumist Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $20.42 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $18.00 | 2024 | Ycanth |
| Shire North American Group INC | $16.71 | 2019 | |
| Tms Neurohealth Centers INC. | $15.14 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.